Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsBio-Theraand STADA have reached an exclusive commercialization and license agreement forBAT2506, a biosimilar candidate to Simponi® (golimumab) Bio-Thera will maintain responsibility fordevelopment, manufacturing, and supply of BAT2506 STADA willhav...
GUANGZHOU, China - Bio-Thera Solutions (688177.SH), a commercial-stage biopharmaceutical company developinginnovative therapies and biosimilars, announced that its partner, Biogen Inc.(Nasdaq: BIIB) officially launched TOFIDENCE (tocilizumab-bavi) in...
Guangzhou, China -- Bio-Thera Solutions(688177:SH), a commercial-stage biopharmaceutical company developing a pipelineof innovative therapies and biosimilars, today announced receiving INDclearance from the US FDA for a phase II Study for BAT8006, an...
